AstraZeneca Secures US FDA Approval for Hypertension Treatment Baxfendy
18 maj, 08:29
02:29 AM EDT, 05/18/2026 (MT Newswires) -- AstraZeneca (AZN.L, AZN.ST) said Monday the US Food and Drug Administration approved Baxfendy as a first-in-class aldosterone synthase inhibitor treatment for adult patients with uncontrolled or resistant hypertension.
The US regulator's clearance of Baxfendy's use in combination with other antihypertensive medications was based on the data of its BaxHTN Phase III study, which showed a statistically significant and clinically meaningful reduction in seated systolic blood pressure at both 2-milligram and 1-milligram doses.
The British drugmaker added that the drug was also generally well-tolerated in patients.
Ämnen i artikeln
AstraZeneca Secures US FDA Approval for Hypertension Treatment Baxfendy
18 maj, 08:29
02:29 AM EDT, 05/18/2026 (MT Newswires) -- AstraZeneca (AZN.L, AZN.ST) said Monday the US Food and Drug Administration approved Baxfendy as a first-in-class aldosterone synthase inhibitor treatment for adult patients with uncontrolled or resistant hypertension.
The US regulator's clearance of Baxfendy's use in combination with other antihypertensive medications was based on the data of its BaxHTN Phase III study, which showed a statistically significant and clinically meaningful reduction in seated systolic blood pressure at both 2-milligram and 1-milligram doses.
The British drugmaker added that the drug was also generally well-tolerated in patients.
Ämnen i artikeln
Din ekonomi
Analyser
Din ekonomi
Analyser
Marknadsöversikt
1 DAG %
Senast
1 mån
